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SUMMARY – Recently an increase has been reported in the number of HBV transmissions from 
anti-HBc positive blood donors that were repeatedly negative in HBsAg and nucleic acid testing us-
ing the most sensitive tests available. The aim of the study was to show the effect of anti-HBc antibody 
testing performed in 2006 on permanent deferral of voluntary blood donors (VBDs), and to estimate 
occult hepatitis B infection (OBI) rate in this population after the introduction of mandatory mo-
lecular testing in the 2013-2016 period. More than 30,000 blood donations collected during the 
2005-2007 period and more than 14,000 VBDs having donated blood during the 2013-2016 period 
after the introduction of molecular testing from eastern Croatia were included in the study. Serologic 
testing was performed with HBsAg assay throughout the study period, and anti-HBc assay was only 
performed in 2006. As part of the confirmatory algorithm testing, all HBsAg positive and unclear 
results were tested with molecular tests. Anti-HBc prevalence among VBDs in 2006 was 1.5%, with 
a rate of 1:197, whereas HBsAg prevalence was stable from 2005 to 2007 (0.04%, 0.1% and 0.1%, 
respectively). The calculated OBI rate from 2013 to 2016 was 1:30,250. Ten of 161 (12.4%) VBDs had 
serologic anti-HBc-only pattern. Anti-HBc testing in 2006 resulted in statistically more deferrals of 
VBDs compared to 2005 and 2007, and to the rest of Republic of Croatia. The strategy of universal 
anti-HBc testing of VBDs in addition to the existing HBsAg and molecular screening could be an 
additional measure to prevent HBV transmission by blood and blood components.
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Introduction
Viral infections are a major cause of liver disease all 
over the world1. It is known that there are five primary 
hepatitis viruses, A, B, C, D and E. Other viruses such 
as cytomegalovirus, Epstein-Barr virus, herpes simplex 
virus, varicella zoster virus, human herpesvirus-6, ade-
novirus and yellow fever virus, as well as drugs, poi-
sons, autoimmune hepatitis and Wilson’s disease can 
cause acute or chronic hepatitis. Each hepatitis virus 
can cause acute hepatitis, but only hepatitis B, C and 
D can cause chronic hepatitis2. Hepatitis E virus can 
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sometimes be the cause of chronic hepatitis in immu-
nocompromised individuals3.
Hepatitis B is a disease caused by hepatitis B virus 
(HBV) belonging to the Hepadnaviridae family and 
has traditionally eight genotypes (A-H, and recently 
reported J), which are geographically widespread. Ac-
cording to the European Association for the Study of 
Liver, chronic HBV infection is divided into five phas-
es that are not strictly separated and stable, as follows: 
(I) HBeAg-positive chronic infection, (II) HBeAg-
positive chronic hepatitis, (III) HBeAg-negative 
chronic infection, (IV) HBeAg-negative chronic hepa-
titis, and (V) HBsAg-negative phase4. Hepatitis B is a 
viral infection responsible for most chronic liver disease 
patients and is transmitted parenterally, as a sexually 
transmitted disease and by vertical transmission from 
mother to child. About 240 million people worldwide 
are infected with this virus and they have a risk of de-
veloping liver cirrhosis and hepatocellular carcinoma5.
Although in the last two decades, major steps have 
been taken to reduce the risk of infection by blood 
transfusions, HBV is still a global risk in transfusion 
medicine. The residual risk of HBV is not restricted to 
the ‘window period’, but has been increased by includ-
ing blood donors with occult hepatitis B infection 
(OBI), a condition when HBV DNA is present in the 
liver or plasma with undetectable HBsAg (hepatitis B 
surface antigen) and with or without anti-HBc anti-
bodies (hepatitis B core, core refers to hepatitis B anti-
gen) or anti-HBs, outside the ‘window period’6. Up-
dated statements of the Taormina Consensus Confer-
ence state that OBI is the presence of replication com-
petent HBV DNA in the liver and/or HBV DNA in 
blood with HBsAg negative result by currently avail-
able assays with or without anti-HBc or anti-HBs7. 
When detectable, the amount of HBV DNA in serum 
is usually very low (<200 IU/mL). For more than thir-
ty years, it has been known that HBsAg negative and 
anti-HBc positive blood donors can transmit HBV8.
The introduction of molecular assays in blood 
 donor testing has led to understanding the additional 
effect of anti-HBc marker in the detection of OBI, but 
a qualitative anti-HBc test can discriminate poten-
tially infectious rather than truly infectious donors, 
making its use in high-prevalence populations condi-
tioned with parallel molecular testing, antibody titer 
testing or other HBV marker testing9-12. Recently, in-
creasing evidence of HBV transmissions from anti-
HBc positive blood donors that were repeatedly nega-
tive in HBsAg and HBV individual nucleic acid test-
ing (ID-NAT) using the most sensitive tests available 
has been reported13.
In 2013, Croatia implemented the ID-NAT as a 
mandatory blood donor test for three viruses, i.e. HBV, 
hepatitis C virus (HCV) and human immunodefi-
ciency virus (HIV -1) for all donations. In 2016, HIV-2 
was added with the new ID-NAT test. Although the 
risk of transmissible infectious diseases in Croatia has 
been reduced significantly by the use of serologic tests 
(HBsAg, anti-HCV, anti-TP, HIV Ag/Ab) and con-
sistent application of blood donor selection criteria, 
the notable challenge for transfusion therapy in Croa-
tia was the risk of HBV transmission due to OBI. 
VBDs with positive anti-HBc results are deferred for 
further donations, regardless of anti-HBs status.
Transfusion service in eastern Croatia was reorga-
nized in the 2011-2014 period. The Clinical Depart-
ment of Transfusion Medicine (CDTM) of the Osijek 
University Hospital Centre (Osijek UHC) has taken 
over the tasks of collecting, testing, producing and 
supplying blood preparations for the hospitals in 
Našice, Vukovar, Vinkovci, Virovitica, Slavonski Brod 
and Nova Gradiška. Previously, these hospitals per-
formed the above mentioned tasks for their needs. 
Currently, CDTM supplies blood to a total of seven 
hospitals and as a licensed health care facility for blood 
collection and supply is the second largest blood bank 
in the Republic of Croatia with over 30,000 blood do-
nations collected annually since 2017.
The objective of the present study was to show the 
effect of testing VBDs for anti-HBc antibody with de-
tection of total antibodies (IgM and IgG classes) on 
VBD permanent deferral, and to estimate OBI rate in 
VBDs at the Osijek UHC CDTM after the introduc-
tion of mandatory ID-NAT testing. The results of HB-
sAg testing in blood donations collected in the Osijek-
Baranja County in 2005, 2006 and 2007 were analyzed, 
as well as the results of anti-HBc antibody testing in 
2006 and HBsAg test results for the total number of 
donations collected in the Republic of Croatia.
Materials and Methods
Blood samples
The study included 10,579 serum samples from 
blood donations in 2005, 10,398 serum samples in 2006 
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and 10,561 serum samples in 2007 collected from 
VBDs in eastern Croatia (including the population of 5 
counties: Osijek-Baranja, Vukovar-Srijem, Brod-Posav-
ina, Požega-Slavonija and Virovitica-Podravina, with 
about 800,000 inhabitants). Blood samples were ex-
tracted in 10-mL Becton-Dickinson tube without anti-
coagulant and after the fibrin cluster was formed, they 
were centrifuged for 10 minutes at 3000 rpm.
Serologic testing
Serologic testing was performed by the micropar-
ticle enzyme immunoassay HBsAg (V2) on an Ax-
SYM analyzer (Abbott, TX, USA) and anti-HBc che-
miluminescence immunoassay on a Vitros ECIQ ana-
lyzer (Ortho Clinical Diagnostics, NJ, USA).
For statistical calculations, the number of VBDs 
tested in the Osijek-Baranja County that were rejected 
on the basis of serum markers was compared with the 
total number of VBDs tested in the Republic of Croa-
tia; the latter data were kindly provided by the Croa-
tian Institute of Transfusion Medicine, Zagreb.
Molecular testing
As part of confirmatory algorithm testing in 2005, 
2006 and 2007, all HBsAg positive and unclear results 
were sent to the CDTM for HBV DNA testing with 
the HPS/HBV Cobas TaqMan 48 test; sensitivity 6 
IU/mL. In the 2013-2016 period, the Procleix Ultrio 
Plus test with 95% level of detection for HBV, 3.4 IU/
mL was used on ID-NAT.
Ethics
All the procedures in the study were in accordance 
with ethical standards of the institutional or regional 
board on human experimentation and Helsinki Decla-
ration of 1975, as revised in 1983.
Statistical methods
The results of the study were processed by descrip-
tive and tabular statistics. Categorical data were ex-
pressed as absolute and relative frequencies and statis-
tically analyzed by χ2-test or Fisher exact test using 
Table 1. Testing results of VBDs for HBsAg and anti-HBc at the Clinical Institute of Transfusion Medicine,  
Osijek University Hospital Centre and in Republic of Croatia
Number (%) of VBDs/donations tested
p*Osijek-Baranja 
County, n (%)
Other centers  




HBsAg positive 4 (0.04) 41 (0.03) 45 (0.03) 0.53HBsAg negative 10,575 (99.96) 156,946 (99.97) 167,521 (99.97)
Total number of donations tested 10,579 (100) 156,987 (100) 167,566 (100)
2006
HBsAg positive 6 (0.10) 34 (0.02) 40 (0.02) 0.04HBsAg negative 10,392 (99.9) 156,906 (99.98) 167,298 (99.98)
Total number of donations tested 10,398 (100) 156,940 (100) 167,338 (100)
2006
HBsAg positive + anti-HBc positive 167 (1.6) 34 (0.02) 201 (0.10) <0.001HBsAg negative 10,231 (98.4) 156,906 (99.98) 167,137 (99.9)
Total number of donations tested 10,398 (100) 156,940 (100) 167,338 (100)
2007
HBsAg positive 6 (0.10) 29 (0.02) 35 (0.02) 0.02HBsAg negative 10,555 (99.9) 161,009 (99.98) 171,564 (99.98)
Total number of donations tested 10,561 (100) 161,038 (100) 171,599 (100)
*Fisher exact test; VBDs = voluntary blood donors
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Prism 5 (GraphPad Software, San Diego, CA, USA) 
statistical software. The level of statistical significance 
was set at p<0.05.
Results
Anti-HBc testing
In the 2005-2007 period, 31,538 blood donations 
were collected by CDTM in the Osijek-Baranja Coun-
ty. Along with HBsAg testing, in 2006 all donations 
were tested for anti-HBc as well.
There were no significant differences in the number 
of HBsAg positive or negative VBDs in the Osijek-
Baranja County and other Croatian centers in 2005. 
During 2006, there were significantly more HBsAg 
positive VBDs in the Osijek-Baranja County (Fisher 
exact test, p=0.04), and significantly more HBsAg + 
anti-HBc positive VBDs (Fisher exact test, p<0.001) 
as compared to other centers in the Republic of Croa-
tia. In 2007, there were significantly more HBsAg 
positive VBDs in the Osijek-Baranja County than in 
other centers in the Republic of Croatia (Fisher exact 
test, p=0.02) (Table 1).
Deferral of VBDs due to positive anti-HBc test
During 2005 and 2007, Osijek UHC did not use 
anti-HBc and other HBV markers. In 2006, of the to-
tal number of donations tested in Osijek UHC, there 
were 6 (0.06%) HBsAg positive (and anti-HBc posi-
tive together with/without other HBV markers) 
VBDs, 161 (1.5%) anti-HBc positive VBDs including 
21 (0.02%) only-anti-HBc positive VBDs, and 140 
(1.3%) VBDs positive for other HBV markers as well. 
Anti-HBc positive VBDs were not reconfirmed with 
other anti-HBc assay but additional follow-up sample 
was obtained and testing for other HBV markers was 
performed. HBsAg and all anti-HBc positive VBDs 
were permanently deferred (Table 2). In 2006, there 
were significantly more permanently deferred repeat 
VBDs in Osijek-Baranja County compared to other 
Table 2. Number of permanently deferred VBDs at the Clinical Institute of Transfusion Medicine, Osijek University 
Hospital Centre







Other positive HBV 
markers
Total number of 
donations tested
2005 4 Not performed Not performed Not performed 10,579
2006 6 161 21 140 10,398
2007 6 Not performed Not performed Not performed 10,561
Total 16 161 20 140 31,538
VBDs = voluntary blood donors
Table 3. Distribution of permanently deferred VBDs due 
to HBV testing relative to the number of blood donations 
at the Clinical Institute of Transfusion Medicine, Osijek 
University Hospital Centre and in Republic of Croatia












VBDs 3 (75) 12 (29.1) 15 (33.3) 0.10New 
VBDs 1 (25) 29 (70.7) 30 (66.7)
Total 4 (100) 41 (100) 45 (100)
2006†
Repeat 
VBDs 155 (92.8) 8 (23.5) 163 (81.1) <0.001New 
VBDs 12 (7.2) 26 (76.5) 38 (18.9)
Total 167 (100) 34 (100) 201 (100)
2007
Repeat 
VBDs 2 (33.3) 8 (27.6) 10 (28.6) >0.99New 
VBDs 4 (66.7) 21 (72.4) 25 (71.4)
Total 6 (100) 29 (100) 35 (100)
*Fisher exact test; VBDs = voluntary blood donors; CDTM = Cli-
nical Department of Transfusion Medicine; Osijek UHC = Osijek 
University Hospital Centre; †HBV testing included HBsAg + anti-
HBc assays
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centers in the Republic of Croatia (Fisher exact test, 
p<0.001), whereas in 2005 and 2007 there were no sig-
nificant differences between Osijek UHC and other 
centers in Croatia (Table 3). HBV serologic profiles 
of permanently deferred VBDs at the Osijek UHC 
CDTM in 2006 are shown separately in Table 4.
OBI rate from 2013 to 2016
In the period from May 1, 2013 until the end of 
2016, eight cases of OBI were recorded, one in the 
Osijek-Baranja County and 7 in the other four coun-
ties (Vukovar-Srijem, Požega-Slavonija, Brod-Posavi-
na and Virovitica-Podravina). Only in the last six 
months of 2013, there were significantly more OBIs in 
the other four counties than in Osijek-Baranja Coun-
ty, whereas in the 2014-2016 period there were no sig-
nificant differences in the number of OBIs (Table 5). 
Detailed report of eight cases of OBI among VBDs 
diagnosed at the Osijek UHC CDTM during the 
study period is shown in Table 6.
Table 4. HBV serologic profiles of permanently deferred VBDs at the Clinical Institute of Transfusion Medicine,  
Osijek University Hospital Centre in 2006
Anti-HBc 
only positive
Anti-HBc + anti-HBs 
+ anti-HBe positive
Anti-HBc +  
anti-HBs positive
Anti-HBc +  
anti-HBe positive Total
HBsAg positive 0 0 0 6 6
HBsAg negative 21 68 64 8 161
Total 21 68* 64 14 167
VBDs = voluntary blood donors; *one VBD had HBeAg positive result; the range of anti-HBs titer was 12-1000 mIU/mL
Table 5. Distribution of occult HBV infection frequency and permanent deferral of VBDs relative to the number  
of blood donations in the Clinical Institute of Transfusion Medicine, Osijek University Hospital Centre and other  
4 counties in the 2013-2016 period
Number (%) VBDs tested
p*Osijek-Baranja 
County, n (%)




2013 (May 1 to Dec 31)
OBI positive 0 4 (0.1) 4 (0.04) 0.02OBI negative 5,922 (100) 3,173 (99.9) 9,095 (99.96)
Total number of VBDs tested 5,922 (100) 3,177 (100) 9,099 (100)
2014
OBI positive 1 (0.01) 1 (0.02) 2 (0.01) >0.99OBI negative 7,462 (99.99) 6,183 (99.98) 13,645 (99.99)
Total number of VBDs tested 7,463 (100) 6,184 (100) 13,647 (100)
2015
OBI positive 0 2 (0.03) 2 (0.01) 0.17OBI negative 8,728 (100) 6,118 (99.97) 14,846 (99.99)
Total number of VBDs tested 8,728 (100) 6,120 (100) 14,848 (100)
2016
OBI positive 0 0 0 -OBI negative 8,137 (100) 6,182 (100) 14,319 (100)
Total number of VBDs tested 8,137 (100) 6,182 (100) 14,319 (100)
*Fisher exact test; VBDs = voluntary blood donors; †Vukovar-Srijem, Požega-Slavonija, Brod-Posavina and Virovitica-Podravina; OBI = 
occult HBV infection
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Discussion and Conclusion
The anti-HBc test was introduced into routine 
blood screening in the mid-1980s in HBV ethnically 
diverse countries such as the USA. In 1989, Japan in-
troduced an anti-HBc blood donor test with a modi-
fied algorithm in which anti-HBc reactive with <1:32 
or ≥32 with anti-HBs ≥200 mIU/mL levels were ac-
cepted for transfusion. The prevalence of anti-HBc is 
related to regional HBV prevalence (USA 0.23%, UK 
0.56%, Germany 1.88%, Italy 4.85%, India 10.82%, 
Greece 14.9%, etc.)13-16. In Italy, in 2013, there was no 
recommendation for anti-HBc testing in routine prac-
tice due to the relatively high prevalence of other sero-
logic infections (HBsAg and/or HBV DNA). The 
number of rejected VBDs would therefore be too large 
and unacceptable for this reason16. While OBI preva-
lence in VBD population varies from 0.0002% to 
0.084%15,17-20, it is 0.18% in China, which is a highly 
endemic HBV region21. According to data from the 
Croatian Public Health Institute, at the beginning of 
the 21st century, the prevalence of HBs Ag in new 
blood donors was 0.4% (in 2002) versus 0.1% in 2011, 
continuing to decrease to 0.047% in 201822-24 . Based 
on the HBsAg seroprevalence data in different popu-
lation subgroups, it is estimated that approximately 
20,000-30,000 people in Croatia are chronically in-
fected with HBV25.
The results of this study showed the prevalence of 
anti-HBc among VBDs in eastern Croatia (Osijek-
Baranja County) in 2006 to be 1.5%, with a rate of 
1:197, while the HBsAg prevalence during the 2005-
2007 period was stable (0.04%, 0.1% and 0.1%, respec-
tively). The calculated OBI rate from 2013 to 2016 was 
1:30,250. Ten of 161 (12.4%) VBDs had the anti-
HBc-only pattern. Considering that in Croatia anti-
HBc test is not obligatory in VBD screening, VBDs 
with anti-HBc positive results are permanently de-
ferred for blood donation and there is no re-entry na-
tional policy using anti-HBs results, anti-HBc testing 
in 2006 resulted in a statistically higher VBD deferral 
compared with 2005 and 2007, and with the rest of the 
Republic of Croatia. The number of VBDs lost after 
anti-HBc screening at the Osijek UHC CDTM was 
substantial although it did not significantly affect the 
overall blood supply. It is important to note that in 
2006, VBDs from Osijek-Baranja County were 
screened for anti-HBc, while VBDs from the other 
four counties whose serologic screening testing was 
taken over by the Osijek UHC CDTM in 2011-2014 
were not tested for anti-HBc. The results of ID-NAT 
testing revealed that all seven VBDs where OBI was 
detected were from those counties, except for a new 
VBD from the Osijek-Baranja County who donated 
blood for the first time. The result of our research on a 
larger number of permanently deferred repeat blood 
donors (repeat VBDs/new VBDs=155/12) coincides 
with the OBI prevalence in the Republic of Croatia, 
which is significantly higher among multiple blood 
donors (45/50, 90%), male sex (86%) and older donors 
(median age 58) in relation to the general population 
of blood donors26. In addition, it is also apparent from 
the results that after the introduction of routine ID-
NAT testing, OBI had a declining tendency in the 
eastern part of Croatia in 2013, 2014, 2015 and 2016.
Table 6. Detailed report of eight cases of occult HBV infections among VBDs diagnosed at the Clinical Institute  
of Transfusion Medicine, Osijek University Hospital Centre during study period
Year Case/donor* Age (yrs) HBV-DNA (IU/mL) Anti-HBc Anti-HBs (IU/L) Anti-HBe
2013 OBI 1 58 <20 Pos 24 Neg
2013 OBI 2 51 ND Pos 12 Neg
2013 OBI 3 64 ND Pos Neg Neg
2013 OBI 4 52 ND Pos 789 Pos
2014 OBI 5 52 <20 Pos 24 Neg
2014 OBI 6 35 <20 Pos Neg Pos
2015 OBI 7 61 NP Pos NP NP
2015 OBI 8 56 ND Pos 18 Neg
VBDs = voluntary blood donors; OBI = occult HBV infection; ND = not determined; NP = not performed; Pos = positive; Neg = negative; 
*all eight cases were anti-HBc IgM and HBeAg negative
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According to a recent study in Croatian donors 
conducted over a 14-year period, the anti-HBc preva-
lence significantly decreased among Croatian VBDs 
(from the Croatian Institute of Transfusion Medicine), 
from 5.24% in 2004 through 2.56% in 2013 to 1.32% 
in 201727. Similarly, the prevalence of anti-HBc-only 
profiles decreased from 0.62% in 2004 through 0.25% 
in 2013 to 0.21% in 2017. A fourfold decrease was ob-
served in all age groups of VBDs from 2017 but most-
ly among repeat donors (from 5.90% to 1.38%). In the 
group of first-time donors, there was a nonsignificant 
difference in anti-HBc prevalence during the study 
period, probably due to their younger age (<29 years), 
and were mostly vaccinated against HBV according to 
the mandatory vaccination policy in Croatia since 
199927.
However, similar anti-HBs carriage rates (80.56%, 
87.57%, and 82.09%) were reported in anti-HBc posi-
tive donors during the study period. HBsAg and HBV 
DNA were not detected. In the first year of blood do-
nor testing in Croatia with ID-NAT tests (2013), the 
frequency of OBI was 1:7,031, whereas after the 3-year 
period it was 1:10,900 donations, followed by further 
significant decrease, i.e. 1:98,494 in 2016, 1:28,495 in 
2017 and 1:195,815 in 2018. Analysis of 23 OBI do-
nor archival samples showed consistency of anti-HBc 
positive results (100%), as opposed to ID-NAT (63%) 
and ID-NAT reproducibility (50%), as expected for 
samples with a low HBV DNA viral load. These data 
support the importance of anti-HBc testing in identi-
fying OBI donors. HBV decreasing residual risks of 
68, 88, and 12 per million donations were estimated for 
the years 2004, 2013 and 201727.
Taking into consideration that anti-HBc per se is 
an irreplaceable serologic marker in the detection of 
end phase HBV infection, which preludes convales-
cence in the detection of seropositive OBI infection 
that is characterized by negative HBsAg test and HBV 
DNA blood level is mostly undetectable or intermit-
tent, it is assumed that anti-HBc would be a more use-
ful marker in the detection of OBI in VBDs. Results 
of this study, the anti-HBc rate/OBI rate (1:197/ 
1:30,250) and the previous Croatian study from 2013 
(anti-HBc rate/OBI rate 1:19/1:11,213; 2017 anti-
HBc rate/OBI rate 1:76/1:30,932) show that due to 
the high consistency of anti-HBc in Croatian OBI 
VBDs, the strategy of universal testing of blood do-
nors for this marker in addition to the existing HBsAg 
and ID-NAT screening in Croatia would represent an 
additional measure to prevent HBV transmission by 
blood and blood components.
The true value of universal anti-HBc screening of 
blood donors remains controversial and mostly de-
pends on HBV prevalence in a population. It is esti-
mated that in moderate- and high-endemic countries, 
where anti-HBc prevalence in blood donors ranges 
between 8% and >50%, such as the Mediterranean 
area, East Asia, and sub-Saharan Africa, anti-HBc 
testing would affect blood product availability too se-
verely and probably cannot be implemented without 
compromising blood supplies13.
Similarly, universal VBD anti-HBc testing in HBV 
low-endemic countries is still debated. While some 
HBV low-endemic and developed countries such as 
Germany and the Netherlands in EU, as well as Can-
ada, have recently implemented anti-HBc screening, 
some other developed countries, i.e. Australia and 
Switzerland, have not implemented it but decided to 
introduce different strategies to reduce the risk of 
HBV infection (i.e. NAT testing)28.
It is well recognized that anti-HBc may be the only 
detectable serologic marker of HBV infection in blood 
donors, which may be an HBV-naïve subject (false 
positive anti-HBc test), a person with a past HBV in-
fection, or having OBI, i.e. a low-level carrier negative 
for HBsAg29. False positivity of anti-HBc test is one of 
the possible outcomes and such isolated test reactivity 
can be overcome by additional testing with alternative 
anti-HBc assay, as well as testing for other HBV mark-
ers and HBV DNA, which could provide additional 
helpful information, along with additional sample 
testing.
Occult HBV infection is considered a rare event in 
developed low-endemic HBV countries, whereas in 
developing moderate- and high-endemic countries 
the risk is much higher and depends on screening pol-
icies and methods implemented. A recently conducted 
study in Croatia during a three-year period showed 
the incidence of OBI infection of 1 per 10,900 dona-
tions. Since 2013, the Croatian screening policy for 
blood borne viruses includes NAT screening, which 
resulted in deferral of 50 VBDs with OBI and there 
were only two potential HBV DNA transmissions to 
blood recipients in Croatia due to OBI in VBDs26.
The requirements for safe transfusion therapy are 
increasing and new history exclusion criteria for blood 
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donors are constantly being added. At the same time, 
due to the growing demand for blood products and 
prolonged life span, medical procedures are becoming 
ever more complicated and there is no appropriate 
synthetic replacement for all the functions blood car-
ries. Some authors point out that with the current 
strategy, in the near future, we will not be able to meet 
the needs for blood and blood products30. So further 
cost-benefit analyses should be conducted concerning 
decision of including mandatory anti-HBc testing in 
the existing VBD screening strategy in Croatia.
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Sažetak
UTJECAJ POZITIVNOG ANTI-HBc BILJEGA NA TRAJNU ODGODU  
I PROCJENA UČESTALOSTI OKULTNE HEPATITIS B INFEKCIJE  
U POPULACIJI DOBROVOLJNIH DAVATELJA KRVI U ISTOČNOJ HRVATSKOJ
M. Samardžija, D. Drenjančević, M. Miletić, B. Slavulj, I. Jukić, L. Zibar,  
S. Mihaljević, M. Ferenac Kiš i M. Samardžija
U posljednje vrijeme uočen je porast prijenosa HBV infekcije putem krvi dobrovoljnih davatelja koji su pozitivni na 
anti-HBc biljeg, dok su u isto vrijeme ponovljeno negativni u serološkom testiranju na HBsAg biljeg i testiranju tehnikama 
umnožavanja nukleinskih kiselina pričem su korišteni najosjetljiviji dostupni testovi. Cilj ovoga istraživanja bio je ispitati 
utjecaj testiranja anti-HBc biljega provedenog u 2006. godini na trajno odbijanje dobrovoljnih davatelja krvi i procijeniti 
stopu okultne infekcije hepatitis B virusom u navedenoj populaciji nakon uvođenja obveznog molekularnog testiranja u 
razdoblju od 2013. do 2016. godine. U istraživanje je bilo uključeno više od 30.000 donacija pune krvi prikupljenih u raz-
doblju od 2005. do 2007. godine te više od 14.000 dobrovoljnih davatelja koji su donirali krv nakon uvođenja obveznog 
molekularnog testiranja u razdoblju od 2013. do 2016. godine među davateljima s područja istočne Hrvatske. Serološka te-
stiranja HBsAg testom provedena su tijekom cijeloga razdoblja istraživanja, dok je anti-HBc test rađen samo tijekom 2006. 
godine. Kao dio algoritma potvrdnog testiranja svi pozitivni i nejasni rezultati HBsAg testiranja testirani su molekularnim 
testovima. U 2006. godini učestalost pozitivnih anti-HBc biljega među dobrovoljnim davateljima bila je 1,5% sa stopom 
1:197, dok je učestalost pozitivnih HBsAg biljega od 2005. do 2007. godine iznosila 0,04%-0,1%. Izračunata stopa okultne 
infekcije hepatitis B virusom od 2013. do 2016. iznosila je 1:30.250. Isključivo na anti-HBc biljeg pozitivno je bilo 10/161 
(12,4%) dobrovoljnih davatelja. Statistički gledano, testiranje na anti-HBc biljeg u 2006. godini u usporedbi s 2005. i 2007. 
godinom rezultiralo je većim brojem odbijenih dobrovoljnih davatelja u cijeloj Hrvatskoj. Strategija univerzalnog testiranja 
dobrovoljnih davatelja krvi na anti-HBc biljeg uz postojeći test na HBsAg biljeg i molekularni probir može predstavljati 
dodatnu mjeru za sprječavanje prijenosa HBV-a transfuzijom krvi i krvnim pripravcima.
Ključne riječi: Krv, davatelji; Hepatitis B; Hepatitis B virus; Australijski antigen; Hrvatska
